United States: Capitol Hill Healthcare Update May 23, 2017

CBO Score of House Health Bill Set for This Week

Congress's official budget scorekeepers this week will release analysis of the House-approved bill repealing most of the Affordable Care Act (ACA), and that data will inform Senate Republicans on a path for passing their version of the legislation.

The Congressional Budget Office (CBO) and the Joint Tax Committee on Wednesday are scheduled to release analysis – known on Capitol Hill as a "score" – of the House bill, including how much the bill reduces government spending and revised projections of how many Americans could lose insurance coverage.

Under Senate budget rules, that chamber's bill must reduce spending by at least as much as the House's bill. That may create complications for senators who want to provide more generous tax subsidies for people who buy insurance or if the lawmakers want to keep the ACA's Medicaid expansion. Senate Republicans could get around increases in spending by phasing in changes or delaying the repeal of some of the ACA provider taxes and fees – though each of those decisions would provoke other political complications.

Senators met several times last week to discuss next steps on Medicaid, as well as helping insurers offer coverage for pre-existing conditions and creating a short-term fix to stabilize the individual insurance markets. But once they have the CBO score, the Senate GOP's pathway for what can be accomplished politically will become clearer.

Finance Committee Chairman Orrin Hatch (R-Utah) earlier this month wrote to trade associations representing patients, providers and employers seeking feedback on provider taxes, Medicaid, tax credits to purchase healthcare coverage, and funding to stabilize states' individual markets. Hatch asked for responses by Tuesday.

Several Senate Democrats last week said they have had discussions with Republicans about policies they could support in ACA legislation. Despite those attempts at bipartisanship, the healthcare overhaul is likely to remain an all-GOP exercise under the budget reconciliation process, which requires only a simple majority to win Senate approval.

While Democrats would vote for legislation that fixes some of the ACA's shortfalls, they will not support repealing the healthcare law, even in part. Moreover, giving Democrats an opportunity to shape the healthcare bill would run counter to the Senate GOP's political interests, even with President Trump's current political troubles. That's because 10 Democrats face re-election in 2018 in states Trump won, and GOP leaders don't want to give those Democrats bipartisan bona fides ahead of their races.

Some conservative senators – including Sens. Ted Cruz (R-Texas) and Rand Paul (R-Ky.) – said last week that the CBO score and budget reconciliation rules are effectively a legislative straitjacket on Congress. Both senators called for changing Senate rules to allow simple majorities to approve legislation and for overriding rulings from the Senate parliamentarian on what qualifies under a budget reconciliation bill – but GOP leaders said they have no intention of rewriting the chamber's rules.

House Re-Vote on Health Bill? Possible but Not Likely

Some Republican lawmakers were surprised to learn last week that House leaders had not formally transmitted their healthcare bill to the Senate even though the House approved it last month.

The reason for the delay has to do with the CBO's official score of the bill, which is due to be released Wednesday. Under budget rules, the House-approved bill must reduce government spending by at least $2 billion and also not increase the deficit after 10 years. If the CBO determines otherwise, Republicans couldn't use special budget procedures to pass their healthcare bill in the Senate with only 51 votes, rather than the usual 60 needed to approve legislation.

GOP leaders – including House Speaker Paul Ryan – said they are confident their bill will easily meet that $2 billion threshold. An earlier version was scored as saving more than $150 billion, and while GOP leaders did make some changes – like adding $8 billion to subsidize insurers that cover individuals with pre-existing conditions – they say their bill will net out as reducing government spending.

Others aren't so sure, saying the CBO could interpret the last-minute amendment to give states waivers from certain ACA rules as encouraging more people to buy insurance on the individual market and therefore boosting federal outlays. In a worst-case scenario for House Republicans – one that would come with significant political embarrassment – the GOP could act quickly to amend their bill and pass a new version, sending that legislation to the Senate.

Gottlieb to Testify Before House Panel

Dr. Scott Gottlieb will make his first post-confirmation appearance on Capitol Hill when he testifies Thursday before the House appropriations subcommittee that funds the Food and Drug Administration (FDA) budget.

Gottlieb will likely have to defend President Trump's fiscal 2018 budget request, which included a last-minute attempt to derail the user fee reauthorization by requiring drug and medical device companies to pay more than what was agreed to with FDA. He may need to defend proposed Trump budget cuts for the National Institutes of Health and other federal health programs.

Subcommittee Democrats also are likely to use the forum to question Gottlieb on a range of issues related to drug pricing, including importation.

House Panel Set to Approve FDA User Fee Bill

The House Energy and Commerce Committee this week is scheduled to vote on renewing user fees that drug and device companies pay in order to support FDA product reviews.

Last week the panel's health subcommittee endorsed the bill on a voice vote while also approving four amendments, including allowing hearing aids to be sold over the counter, improving access to generic drugs, protecting the U.S. supply chain from counterfeit and diverted drugs, and creating a risk-based process for FDA inspections of medical device facilities.

The Senate HELP Committee earlier this month approved that chamber's version of the user fee bill. Current user fees expire September 30, but congressional leaders want to approve a new five-year agreement in July to avoid disruptions at the FDA, including mandatory layoff notices sent to agency employees whose jobs are tied to user fees.

GOP Nixes Administration Effort to Overturn User Fees

Key House and Senate Republicans last week quickly rejected a last-minute push by the Trump administration to re-write the FDA user fee legislation to increase industry's payments.

The Secretary of the U.S. Department of Health and Human Services Tom Price wrote to congressional leaders last week saying drug and device companies should pay the full cost of product reviews – an idea first floated in President Trump's initial fiscal 2018 budget proposal.

As the House Energy and Commerce Health Subcommittee prepared to vote last week on the user fee agreement, the full committee chairman, Rep. Greg Walden (R-Ore.), ignored Price's pleas. Senate HELP Committee Chairman Lamar Alexander (R-Tenn.), in a one-page letter to Price, wrote that it was "way too late" to upend the delicate agreement struck between the FDA and manufacturers.

Democrats, GOP Urge Trump on Drug Prices

The Congressional Progressive Caucus last week called on President Trump to leverage reauthorization of FDA user fees to address the "skyrocketing costs of prescription drugs."

Rep. Jan Schakowsky (D-Ill.), in a letter to President Trump signed by 35 other liberal House Democrats, called for a series of proposals to address prescription drug costs, including requiring Medicare to negotiate drug prices and requiring drug manufacturers to offer Medicaid-like rebates to Medicare beneficiaries. Each of the group's proposals is a nonstarter with branded drug companies and many congressional Republicans.

Separately, a bipartisan group of senators called on Office of Management and Budget Director Mick Mulvaney to encourage executive action to reduce drug costs. Those senators – Sens. Amy Klobuchar (D-Minn.), John McCain (R-Ariz.) and Chuck Grassley (R-Iowa) – have worked together previously on bipartisan drug-pricing legislation, including bills to allow for importation of medications from Canada.

Mulvaney earlier this month suggested the government press drug companies to provide discounts within Medicare Part D similar to those offered to Medicaid.

Bills Would OK Third-Party Certifications for Devices

Bipartisan legislation introduced in the House and Senate would create a voluntary program under which medical device manufacturers could have their quality systems certified by an FDA-authorized third party, allowing the companies to self-certify certain low-risk changes to currently marketed devices.

Introduced by Sens. Cory Gardner (R-Colo.) and Joe Donnelly (D-Ind.), the Senate bill aims to create a two-year voluntary program under which manufacturers could self-certify certain low-risk changes to currently marketed medical devices approved under the so-called 510(k) pathway. Similar legislation was introduced in the House by Reps. Richard Hudson (R-N.C.) and Larry Bucshon (R-Ind.).

The senators said the change would allow the FDA to target agency resources toward more complex medical technologies and those that require more stringent reviews. Donnelly said the bill would "cut through the red tape at the FDA and safely speed up the approval process."

The legislation won an endorsement from the industry trade association AdvaMed. Some consumer groups object to the bill, saying it weakens FDA by outsourcing safety reviews. Similar language was included in a version of the 21st Century Cures medical innovation legislation that won House approval in 2015 but was dropped from that bill before it became law last year.

Bill Would Streamline FDA Approval for 510(k) Devices

New bipartisan House legislation would allow the FDA to grant 510(k) clearances for moderate-risk medical devices based on compliance with published criteria developed by the agency.

Introduced by Reps. Mimi Walters (R-Calif.) and Ami Bera (D-Calif.), the bill seeks to simplify what the lawmakers say are repetitive and burdensome FDA review requirements for certain low- to moderate-risk medical devices. Even when seeking modifications to certain existing devices, manufacturers must demonstrate to the FDA that their product complies with special controls and is substantially equivalent to the already marketed device.

Walters and Bera say that creates a burden on technology companies to provide duplicate information that also doesn't provide the FDA with meaningful data. Their bill would allow the FDA to identify Class II device types for which sponsors would have the option to seek 510(k) clearance by demonstrating compliance with the FDA's published criteria for that device type, rather than comparing the device to a predicate device already on the market.

Senators Press CMS on Opioid Prescribing Data

Six senators are asking the Centers for Medicare & Medicaid (CMS) for detailed information on how the agency tracks Medicare and Medicaid reimbursement data for opioid prescriptions in an effort to combat abuse of painkillers.

In a letter last week to CMS Administrator Seema Verma, the senators are asking if CMS is analyzing its own data to help curb what they wrote was an "overdose epidemic" with 91 Americans dying each day. The letter was written by Sens. Richard Durbin (D-Ill.), Sherrod Brown (D-Ohio), Angus King (I-Maine), Joe Manchin (D-W.V.), Amy Klobuchar (D-Minn.) and Tammy Duckworth (D-Wis.).

The senators wrote that Medicaid patients are more likely to receive treatment for opioid abuse and are more likely to overdose. They want to know if CMS is adequately using its own Medicare Part D Opioid Prescribing Mapping Tool to identify overprescribing trends. The tool aggregates Part D opioid claims based on geography, prescriber specialty and overall volume.

The letter asked Verma to respond to a series of questions, including whether CMS can establish a similar tracking tool for Medicaid reimbursements.

Senate Panel Approves Package of Chronic Care Measures

The Senate Finance Committee last week unanimously approved legislation expanding Medicare's coverage of telehealth services.

The telehealth provision was part of a package of changes that would overhaul Medicare's payment policies for chronic conditions or for those who have suffered strokes. The CHRONIC Care Act, which passed 26-0, would expand a current program for house calls for the elderly, allow for reimbursement of home dialysis treatment, allow accountable care organizations to offer telemedicine services, and allow Medicare and Medicare Advantage plans to reimburse for telemedicine services.

Led by Chairman Orrin Hatch (R-Utah) and the panel's top Democrat, Sen. Ron Wyden (D-Ore.), the committee has been examining how Medicare cares for Americans with chronic conditions and how it reimburses healthcare providers.

It's not clear when the legislation might be scheduled for a vote by the full Senate. House Budget Committee Chairwoman Diane Black (R-Tenn.) is likely to introduce her own chronic care bill in the House, but it's not clear if it will differ from the Senate legislation.

Trump Budget to Be Released This Week

The White House on Tuesday is scheduled to release its fiscal 2018 budget, and lawmakers say they're anticipating steep cuts in entitlement healthcare programs as President Trump seeks to balance the budget in 10 years.

Trump has said Medicare is off-limits to changes, but lawmakers say they're anticipating cuts to income-linked healthcare programs, including the Medicaid spending reductions that are part of the American Health Care Act and the Children's Health Insurance Program, which is facing a September 30 deadline for reauthorization.

Congress isn't obligated to enact Trump's budget; in fact, White House budgets are more about establishing presidential priorities. Still, the budget could set the baseline for spending discussions on Capitol Hill in the months to come before the start of fiscal 2018 on October 1.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.